Other CNS-active drugs by drug class among those exposed to Schedule II stimulants in 2020
| Prescriptions | Persons | |
| No (%) | No (%)* | |
| Drug class† | ||
| Anticonvulsant | 225 592 (10.3) | 38 112 (13.8) |
| Antidepressant | 987 582 (45.1) | 131 485 (47.6) |
| Antipsychotic | 143 611 (6.6) | 22 650 (8.2) |
| Anxiolytic/sedative/ hypnotic | 540 619 (24.7) | 85 166 (30.8) |
| CNS other | 75 613 (3.5) | 14 558 (5.3) |
| Opioids other | 48 257 (2.2) | 11 322 (4.1) |
| Opioids Schedule II | 149 368 (6.8) | 42 713 (15.5) |
| Stimulant other | 19 705 (0.9) | 4 368 (1.6) |
Source: MarketScan Research Databases, 2019–2020, commercially insured adults, age 19–64 years. Schedule II stimulants include amphetamine and methylphenidate drug products.
*Per cent totals by person do not add to 100 due to patients taking multiple medications.
†Drug classes defined in Micromedex RED BOOK for 2020.
CNS, central nervous system.